GOVX news

GeoVax Labs, Inc. signed a five-year $30 million revolving loan facility with a public limited hedge fund, enabling the company to borrow funds as needed. This capital is intended to fund working capital and general corporate purposes, strengthening the company's financial position.

GeoVax requested a hearing before the Nasdaq Hearings Panel to appeal a bid price delisting trigger, with the hearing scheduled for October 13, 2026, following a request to stay suspension actions.

GeoVax Labs reported second-quarter financial results and advanced operations to prepare for the planned fourth-quarter initiation of a pivotal GEO-MVA immunobridging study under an expedited regulatory pathway, while continuing to develop its Gedeptin immuno-oncology platform.